|Title:||Treatment of tardive dyskinesia in mammals|
|Abstract:||A method of Treatment of Tardive Dyskinesia (TD) in humans by the administration of the compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof in a non-toxic, effective therapeutic amount (calculated as base) to a human in need thereof.|
|Inventor(s):||Stern; Warren C. (Raleigh, NC)|
|Assignee:||Burroughs Wellcome Co. (Research Triangle Park, NC)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Delivery; Dosage form;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.